A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis
1997; Springer Science+Business Media; Volume: 7; Issue: 5 Linguagem: Inglês
10.1007/pl00004152
ISSN1433-2965
AutoresB. Clemmesen, Pernille Ravn, B. Zegels, A. N. Taquet, Claus Christiansen, J.-Y. Reginster,
Tópico(s)Bone Metabolism and Diseases
Referência(s)